Stokes T, Hector AJ, Morton RW, McGlory C, Phillips SM
their safety, their tolerability and their efficacy are all for that dose that's been studied
312 , E224E233 (2017)
Tirzepatide activates both GLP-1 and GIP receptors, engaging a dual mechanism that may produce more potent weight loss and metabolic effects in some patients
A provider evaluation is the most reliable way to determine whether Tirzepatide is appropriate and whether insurance documentation may support coverage
In the US, the advent of TrumpRx means that the prices of Wegovy and Ozempic will fall substantially even before LOE in the early 2030s (for reference, the cash-pay price of Wegovy has dropped ~33% in the last year alone), potentially softening the commercial impact of genericisation